Objective. To determine the predictive value of mid-regional proadrenomedullin (MR-proADM) in comparison with routine clinical and laboratory data in patients with the new coronavirus infection. Material and methods. A prospective single-center study included 97 adults aged 63 years (range 26.2—93.9) with COVID-19 infection and community-acquired pneumonia. In all patients, serum MR-proADM was analyzed upon admission in addition to routine clinical and laboratory analysis. KRYPTOR compact PLUS analyzer and appropriate kits of reagents (BRAHMS GmbH, Ger-many) were applied. We used News scale (National Early Warning Score) for primary assessment of patient condition. All patients were divided into 2 groups depending on the outcome of disease. Group 1 comprised of 83 (85.6%) patients who were discharged with recovery or improvement, group 2 — those who died in the hospital (n=14, 14.4%). Data are presented as absolute values, percentage, median and interquartile range (25—75 percentile). Mann—Whitney U-test was used to compare the variables. Differences were significant at p-value